SCHEDULE: Lynx1 Capital Management Reports Stake in TScan Therapeutics

Lynx1 Capital Management LP and Weston Nichols have reported beneficial ownership of 13.1% of TScan Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• Lynx1 Capital Management LP and Weston Nichols have filed an amended Schedule 13G, reporting their beneficial ownership of TScan Therapeutics, Inc. common stock.
• As of June 30, 2026, the Reporting Persons collectively beneficially own 20,519,148 shares of Voting Common Stock.
• This ownership represents 13.1% of the class of securities outstanding.
• The filing indicates shared voting and dispositive power over these shares.
• The shares are held by Lynx1 Master Fund LP, with Lynx1 Capital Management LP acting as the investment manager and Weston Nichols as the sole member of the general partner.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new operational or financial disclosures.

Positives

• Clear disclosure of beneficial ownership, providing transparency to the market.
• The filing confirms a significant stake (13.1%) held by an investment entity, which could indicate confidence in the company's long-term prospects.

Negatives

• The filing does not contain new financial performance data or strategic updates, limiting insights into the company's current operational health.
• The nature of the investment (passive vs. active) is not detailed beyond the standard certification for Schedule 13G filings.

Risks

• Potential for increased market volatility if the Reporting Persons decide to significantly alter their stake.
• Concentration of ownership by a single entity could influence corporate governance decisions, though the filing certifies no intent to influence control.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from TScan Therapeutics. It solely reports on beneficial ownership as of a specific date.

Management Comments

• The filing should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant stake disclosures via Schedule 13G filings are common in the biotechnology sector, often indicating institutional interest or strategic investment. This filing places Lynx1 Capital Management as a notable shareholder in TScan Therapeutics.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership concentration. Potential for increased trading volume if the stake is actively managed.
• Management: Awareness of a substantial shareholder whose investment strategy could influence future corporate actions, despite certifications to the contrary.

Next Steps

• Monitor future filings from Lynx1 Capital Management and Weston Nichols for any changes in their beneficial ownership.
• Observe TScan Therapeutics' future performance and strategic announcements for potential impact of significant shareholder presence.

Key Dates

Keywords

TScan Therapeutics, Lynx1 Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Shareholder